Summary
This study is open to adults aged 18 and older or above legal age who have a specific
type of advanced neuroendocrine cancer (NEC). Their tumours must be positive for a marker
called DLL3.
The purpose of this study is to test a medicine called BI 764532 in addition to
chemotherapy. The study has Part A1, Part A2, and Part B. Part A1 of this study aims to
find out the highest dose of BI 764532 that people can tolerate in addition to
chemotherapy. Part A2 of this study is to find out how well people tolerate a low dose of
BI 764532 combined with the chemotherapy. The purpose of Part B is to find out how well
people can tolerate BI 764532 in combination with different chemotherapies. Researchers
also want to find out whether BI 764532 in combination with chemotherapy helps people
with NEC.
Participants get different doses of BI 764532 as an infusion into a vein. In addition,
they get platinum-based chemotherapy as infusions into a vein. Participants can continue
treatment up to 3 years if they benefit from treatment and can tolerate it.
Participants visit their doctors regularly. During these visits, the doctors collect
information about participants' health and take note of any unwanted effects. Doctors
also regularly check the size of the tumour.